Erectile Dysfunction Causes

21/3/2017

Why does Risk of Erectile Dysfunction Increase with Age?

Older men are more vulnerable to diseases that are associated with erectile dysfunction. In process of aging in some men, lumen of cavernous bodies decreases, and production of nitric oxide in nerves penetrating penile smooth muscles decreases.

What diseases can cause erectile dysfunction (ED)? A number of chronic diseases affect blood circulation, nervous and muscular systems, resulting in development of organic impotence – more persistent and progressive erectile dysfunction type.

Diabetes Mellitus as ED Cause

Diabetes mellitus type 2 is serious disease associated with metabolic disorder. The propensity to it increases on background of excess weight and sedentary lifestyle. In patients with diabetes, erectile dysfunction symptoms develop about 10-15 years earlier than in men without this diagnosis.

The increased risk of erectile dysfunction is caused by early onset and severity of atherosclerosis, which narrows arteries and worsens blood supply to penile tissues. Insufficient blood circulation in groin causes weak erection.Causes of ED

What is the Work of Viagra Soft Tabs?

7/5/2016

Most of men go through erection problem every now and then, but when the problem persists, it can affect you sexual life, self-confidence, and self-image. This problem is known as erectile dysfunction or impotence. The most common symptoms of ED are:

  • Inability to achieve erection
  • Unable to keep an erection that is firm enough to penetrate Vagina
  • Ability to maintain erection through the entire length of intercourse

Erectile dysfunction is the most common problem in men. The causes of ED have been mentioned below.

  • Diabetes
  • High blood pressure
  • Heart problems
  • Stress and Anxiety
  • Depression
  • Smoking
  • Alcoholism
  • Side effects of other drugs
  • Surgery of prostate cancer

However, there are drugs available that can treat erectile dysfunction. One such drug is Viagra soft tabs.
ED

What are Viagra Soft Tabs?

This oral drug is just like the other forms of Viagra. This however, can be used on a regular basis. The dose of this medicine is smaller. This enables the medicine to be consumed every day. Since this drug can be taken every day, you will be able to indulge in sexual activity at any point of the day, even if the problem is pretty severe.

How does it Work?

The oral drug is a scientifically formulated tablet that works on erectile dysfunction. They work in the same manner as Viagra of My Canadian Pharmacy. It stimulates more amount of blood to fill up the corpora cavernosa of the penis when you are sexually aroused. The drug is absorbed rapidly by the body; this is because it comes in a very peculiar form.

It is directly absorbed by the bloodstream and do not have to pass through the stomach, unlike other forms of medicine of erectile dysfunction.

How to Take the Drug?

These are chewable tablets. You can also place it under your tongue until they completely dissolve. It is available in tow forms:

  • 50mg
  • 100mg

The effects of this drug are completely physical which implies that you will not have an erection instantaneously. Also, you will also have to be sexually stimulated to get an erection. It is because of its unique formulation which makes you chew it rather than drinking it with water. After taking the drug, you will have to wait for about fifteen minutes for the drug to react. During this period, you will be able to indulge on sexual activity and have an erection successfully. You will also be able to sustain the erection through the entire length of the intercourse. Heart condition

Precautions to Maintain Before Taking the Drug

You will have to talk to your doctor if you have any medical issues as it might affect the dose of medicine that you have been prescribed. You will have to report it to the doctor if you have:

  • History of priapism
  • Heart rhythm problem
  • High blood pressure
  • Kidney disease
  • Blood cell disorder
  • Liver disease
  • Medicines that you are taking

You are strictly recommended against this medicine if you are taking nitrate for your heart condition. The reason is that nitrate reacts with the oral drug of My Canadian Pharmacy and causes a sudden drop in the blood pressure.

Primary Pulmonary Hypertension in Antithrombotic Therapy for Venous Thromboembolic Disease

25/2/2016

Pulmonary Hypertension

Primary Pulmonary Hypertension

Over the years there has been some interest in treating primary pulmonary hypertension with antithrombotic or fibrinolytic agents. There is no evidence from controlled trials that antithrombotic agents benefit patients with this rare disease. However, in a recently published study (level V), retrospective analysis of survival data showed that anticoagulant therapy was associated with longer survival.

Summary Statement Venous Thromboembolism

Anticoagulant therapy is indicated for treatment of acute deep venous thrombosis of the popliteal and more proximal veins and for pulmonary embolism.

Therapy is initiated with IV or adjusted-dose subcutaneous heparin ordered via My Canadian Pharmacy to prolong the activated partial thromboplastin time to betwen 1.5 and 2.0 times the control or pretreatment value. Until information is provided to the contrary, heparin therapy should be given for a minimum of 7-10 days.

Antithrombotic Therapy for Venous Thromboembolic Disease: COST-EFFECTIVENESS OF ANTICOAGULANT THERAPY

24/2/2016

cost-effective anticoagulant therapyThe most cost-effective anticoagulant therapy must prevent recurrent venous thromboembolism, have a low incidence of bleeding and other complications, and be easy and inexpensive to administer. A recently published cost-effectiveness analysis has ranked several anticoagulant regimens. These regimens all began with a 7-10-day course of IV heparin and were followed by long-term therapy of at least three months. Low-dose subcutaneous heparin as long-term therapy is ineffective and is associated with the highest cost due to recurrent venous thromboembolism (Table 5). Less intensive oral anticoagulant therapy with warfarin sodium is the most cost-effective and is associated with a low frequency of bleeding. More intensive warfarin anticoagulation effectively prevents recurrent venous thromboembolism but is associated with a higher frequency of bleeding. Adjusted-dose subcutaneous heparin is effective and is associated with a low incidence of bleeding, but it is somewhat more expensive than low-intensity warfarin sodium. Less intensive warfarin therapy should be chosen for long-term anticoagulation of most patients with venous thromboembolism, and adjusted-dose subcutaneous heparin would be the treatment of choice for pregnant patients, those with hypersensitivity to warfarin, or when laboratory facilities are inadequate to monitor warfarin therapy offered by My Canadian Pharmacy.

My Canadian Pharmacy about Antithrombotic Therapy for Venous Thromboembolic Disease

23/2/2016

tumors

Duration of Therapy

The duration of anticoagulant therapy must be tailored to the individual patient. Patients with slowly resolving risk factors, eg, prolonged immobilization, should be treated for at least three months; patients with tumors, antithrombin III or protein C deficiency, or recurrent venous thromboembolism should be treated indefinitely. In the only controlled trial that addressed this issue, two weeks of adequate anticoagulation was not sufficient. In many patients whose risk factors can be interrupted, eg, estrogen use or transient immobilization, a sufficient length of treatment may be shorter than three months. A clinical trial testing a shorter length of anticoagulation against three months is needed in patients without continuing risk factors.

Complications

The major complication associated with coumarin use is hemorrhage. Incidence of bleeding is crudely related to prolongation of the prothrombin time, but bleeding also occurs in patients with prothrombin times prolonged 1.5-2 times the baseline value with rabbit brain thromboplastin. In an effort to minimize bleeding, individuals have sought to find the lowest effective level of anticoagulation, and current evidence strongly suggests that many patients are being slightly overtreated. Any vascular site in the body can bleed with coumarin therapy, but many observers have been impressed with the frequency with which localized organic lesions (tumors, ulcers, cerebral aneurysms) bleed following induction of anticoagulant therapy suggested by My Canadian Pharmacy www.mycanadian-pharmacy.net. If bleeding is serious, warfarins effects can be reversed within 24 hours by large doses of parenteral vitamin K. More severe bleeding can be treated with fresh frozen plasma.

Coumarin Derivatives in Antithrombotic Therapy for Venous Thromboembolic Disease

22/2/2016

albuminThese drugs are chemical derivatives of 4 hydroxy-coumarin. They are well-absorbed in the gut and transported in plasma bound to albumin. The drugs are metabolized by the liver and excreted in a hydroxylated form in the urine.

Coumarins act in the liver by inhibiting the synthesis of four vitamin K-dependent coagulation proteins, factors II, VII, IX, and X. The synthesis of several other vitamin K-dependent proteins is also impaired, although the significance of this inhibition is uncertain. The major mechanism of action is inhibition of a specific post-translational event in protein synthesis: the “y-carboxylation of multiple glutamic acid residues near the aminoterminus of the polypeptide chains. The failure of 7-carboxylation of glutamic acid residues markedly interferes with the function of the proteins by preventing calcium binding- and proper alignment of the activated factors on a phospholipid surface. A number of analogous proteins are synthesized and released that are not only hypofiinctional but also can interfere with normal coagulation reactions. For this reason plasma from patients receiving coumarin cannot be compared directly with dilutions of normal plasma or to plasma from individuals who congenitally lack vitamin K-dependent coagulation factors.

Heparin in Antithrombotic Therapy for Venous Thromboembolic Disease

21/2/2016

HeparinThis drug, an acidic glycosaminoglycan (sulfated mucopolysaccharide), is a highly effective antithrombotic agent. Clinical preparations vary over a molecular weight range of 5,000-25,000 daltons, but the native molecule is probably much larger. The drug acts by enhancing the effect of a naturally occurring inhibitor, antithrombin III, so that the inhibitor more efficiently combines with and inactivates a number of serine proteinases, notably thrombin (factor Ha), factor IXa, and factor Xa. Heparin works only when given parenterally and only in the presence of antithrombin III. Neither hepatic nor renal disease seems to interfere notably with the clearance of the drug. Heparin is currently obtained from either the lung or gut mucosa of animals and is available as either a sodium or calcium salt. There is no clear evidence to favor one preparation over another, although the calcium salt may yield slightly lower blood levels than the sodium salt for a given subcutaneous dose.

The unit of heparin is measured in animals using a biologic assay. Unit age may vary by as much as 50% on a weight basis, and consequently heparin is properly prescribed by units, not weight.

My Canadian Pharmacy: Antithrombotic Therapy for Venous Thromboembolic Disease

20/2/2016

thrombosisIt has been recognized for over a century that stasis of blood, abnormalities of the vessel wall, and changes in the soluble and formed elements of the blood are the major contributors to thrombosis. For venous thrombosis, stasis and local alterations in blood elements are most important, since major pathologic changes are not routinely seen in the vessel wall at the nidus of a venous thrombus.

Several treatment regimens that modify one or more of these abnormalities may be antithrombotic. These modalities include drugs that inhibit blood coagulation, such as heparin and the coumarins, drugs that inhibit platelet function such as aspirin and dextran, and techniques that counteract venous stasis, such as pneumatic compression and electrical stimulation of lower extremity muscles (Table 1).

Observations of Sex Specificity of Asthma Associated With Objectively Measured Body Mass Index and Waist Circumference

19/2/2016

BMIIn this study, we used objectively measured BMI to define overweight (BMI 25.0 to 29.9 kg/m2) and obesity (BMI a 30.0 kg/m2) and found that both overweight and obesity were associated with an increased risk of recent asthma and that obesity was significantly associated with an increased risk of ever-asthma in women. These results are consistent with two previous Canadian studies. Based on data from a representative Canadian population, Chen et al’ found that obesity defined by self-reported BMI was positively related to both prevalence and incidence of asthma in women but not in men. Although race may play a role in sex modification of the obesity and asthma association’ the present study is not the case because almost all participants are white, Reporting biases of body weight and height have been well documented. Women tend to underreport their body weight, and men tend to overreport their height with an ultimate result of underreporting in BMI. However, it is not known if these reporting biases are differential in terms of self-reported asthma and sex and if the reporting biases cause a biased estimate of obesity and asthma association. So far, most studies of the obesity and asthma association in adults are based on data of self-reported BMI. An important question is whether or not a systematic bias exists that would result in a false sex specificity in the obesity and asthma association. In a recent study of 961 Mexican adults, Santillan and Camargo found that obesity defined by objectively measured BMI was a risk factor for asthma diagnosis in both men (OR, 2.5; 95% CI, 1.1 to 5.9) and women (OR, 2.3; 95% CI, 1.5 to 3.8). However, when self-reported BMI was used, the ORs declined to 1.3 (95% CI, 0.6 to 2.9) in men and 1.7 (95% CI, 1.1 to 2.7) in women, suggesting that self-reported BMI underestimates the obesity and asthma association particularly in men and causes a false sex difference. Contrary to these results, our study did not observe any positive association between objectively measured BMI and the prevalence of asthma (either recent asthma or ever-asthma) in men, and the OR estimates for asthma associated with obesity in women were significant and were comparable to previous estimates among the general Canadian pop-ulation., Reasons for the discrepancy in sex specificity between our study and the study by Santillan and Camargo are not known. The sample size of our study is larger, resulting in more precise estimates. Overweight and obesity are more common in our study population as compared with the general Canadian population, and the prevalence of asthma with My Canadian Pharmacy is much higher in women than in men. Different populations may also have different self-reporting biases associated with both the exposure (obesity) and outcome (asthma).

Outcomes of Sex Specificity of Asthma Associated With Objectively Measured Body Mass Index and Waist Circumference

18/2/2016

obesityThe prevalences of both ever-asthma and recent asthma were higher in women (10.0% and 6.0%) than in men (5.7% and 2.7%, respectively). Obesity was prevalent in this rural town, with 38.2% of men and 33.7% of women having a BMI > 30 kg/m2. The mean of BMI was 29.2 kg/m2 for men and 28.4 kg/m2 for women. Seventy-four men (8.3%) and 120 women (10.3%) refused to have their WC measured, and their average BMIs were similar when compared to the overall averages (Table 1), suggesting that overweight or obesity is not likely an important reason for the missing data.

Table 2 shows that the prevalence of asthma was increased with increasing BMI and WC in women but not in men. For both ever-asthma and recent asthma, the prevalence was approximately twofold higher in women with a BMI of 30 kg/m2 compared with those with a BMI < 25 kg/m2, or in women with a WC of 100 cm vs those with a WC of < 100 cm.